NASDAQ:MNPR

Monopar Therapeutics (MNPR) Stock Forecast, Price & News

$0.58

+0.01 (+1.30%)

(As of 05:19 PM ET)

Compare

Today's Range: $0.55
▼
$0.60
50-Day Range: $0.57
▼
$0.87
52-Week Range: $0.53
▼
$4.88

Volume: 6,049 shs
Average Volume: 194,893 shs
Market Capitalization: $8.18 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.33

Monopar Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 1,888.3% Upside
$11.33 Price Target
Short Interest: Healthy
1.13% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.44
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.76) to ($0.62) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.49 out of 5 stars

3.4

Analyst's Opinion

Consensus Rating
Monopar Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.33, Monopar Therapeutics has a forecasted upside of 1,888.3% from its current price of $0.57.
Amount of Analyst Coverage
Monopar Therapeutics has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.13% of the float of Monopar Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Monopar Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Monopar Therapeutics has recently decreased by 33.02%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Monopar Therapeutics does not currently pay a dividend.
Dividend Growth
Monopar Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MNPR.

3.0

News and Social Media Coverage

News Sentiment
Monopar Therapeutics has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Monopar Therapeutics this week, compared to 1 article on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Monopar Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
41.60% of the stock of Monopar Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 6.18% of the stock of Monopar Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Monopar Therapeutics are expected to grow in the coming year, from ($0.76) to ($0.62) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Monopar Therapeutics is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Monopar Therapeutics is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Monopar Therapeutics has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Monopar Therapeutics (NASDAQ:MNPR) Stock

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

MNPR Price History

30 days | 90 days | 365 days | Advanced Chart

MNPR Stock News Headlines

September 28, 2023 | americanbankingnews.com

Short Interest in Monopar Therapeutics Inc. (NASDAQ:MNPR) Decreases By 33.0%

September 5, 2023 | finance.yahoo.com

Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

September 28, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

September 5, 2023 | finance.yahoo.com

Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

August 10, 2023 | finance.yahoo.com

Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments

August 8, 2023 | finance.yahoo.com

Monopar Provides Encouraging Camsirubicin Clinical Data Update

August 8, 2023 | finance.yahoo.com

Monopar Provides Encouraging Camsirubicin Clinical Data Update

July 11, 2023 | finance.yahoo.com

Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore

September 28, 2023 | Micro-Cap Stock Trader (Ad)

Unlock the treasure on Mount Olympus with this little-known mining stock.

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

July 11, 2023 | finance.yahoo.com

Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore

June 21, 2023 | finance.yahoo.com

Monopar to Participate in the Radiopharma Forum by the Lake 2023

June 14, 2023 | finance.yahoo.com

Monopar to Participate in the Maxim Group’s Healthcare Virtual Conference

June 1, 2023 | msn.com

HC Wainwright & Co. Reiterates Monopar Therapeutics (MNPR) Buy Recommendation

June 1, 2023 | finance.yahoo.com

Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update

June 1, 2023 | finance.yahoo.com

Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update

May 29, 2023 | finance.yahoo.com

Monopar Therapeutics Inc. (MNPR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

May 15, 2023 | markets.businessinsider.com

Expert Ratings for Monopar Therapeutics

May 15, 2023 | msn.com

HC Wainwright & Co. Maintains Monopar Therapeutics (MNPR) Buy Recommendation

May 15, 2023 | markets.businessinsider.com

Monopar Therapeutics Inc (MNPR) Gets a Buy from H.C. Wainwright

May 13, 2023 | investing.com

Monopar Therapeutics (MNPR) Earnings Dates & Reports

May 11, 2023 | marketwatch.com

10-Q: MONOPAR THERAPEUTICS

May 11, 2023 | finance.yahoo.com

Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments

May 11, 2023 | finanznachrichten.de

Monopar Therapeutics Inc.: Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments

May 11, 2023 | finance.yahoo.com

Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments

March 30, 2023 | msn.com

Maxim Group Downgrades Monopar Therapeutics (MNPR)

March 29, 2023 | finanznachrichten.de

Monopar Therapeutics Inc.: Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis

March 28, 2023 | marketwatch.com

Monopar Therapeutics Shares Plumb New Lows After Validive Failure >MNPR

See More Headlines

Receive MNPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monopar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MNPR Company Calendar

Last Earnings: 8/10/2023
Today: 9/28/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MNPR
CUSIP: N/A
CIK: 1645469
Web: www.monopartx.com
Phone: 847-388-0349
Fax: N/A
Employees: 11
Year Founded: 2014

Price Target and Rating

Average Stock Price Forecast: $11.33
High Stock Price Forecast: $24.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +1,862.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.76)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,520,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -100.91%
Return on Assets: -79.73%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.12
Quick Ratio: 4.12

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.78 per share
Price / Book: 0.74

Miscellaneous

Outstanding Shares: 14,160,000
Free Float: 8,268,000
Market Cap: $8.18 million
Optionable: Not Optionable
Beta: 0.93

Social Links

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Dr. Chandler D. Robinson M.B.A. (Age 39)
M.D., M.Sc., MBA, MSc, Co-Founder, CEO, Pres & Director
Comp: $708.12k

Ms. Kim R. Tsuchimoto CPA (Age 60)
CFO, Sec., Treasurer & Director
Comp: $350.55k

Mr. Andrew J. Cittadine M.B.A. (Age 51)
Chief Operating Officer
Comp: $390.41k

Dr. Patrice P. Rioux M.D. (Age 72)
Ph.D., Acting Chief Medical Officer

Key Competitors

View All Competitors

Insiders

Andrew Cittadine
Bought 6,053 shares on 11/14/2022
Total: $18,159.00 ($3.00/share)

View All Insider Transactions

MNPR Stock - Frequently Asked Questions

Should I buy or sell Monopar Therapeutics stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Monopar Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MNPR shares.
View MNPR analyst ratings or view top-rated stocks.
What is Monopar Therapeutics' stock price forecast for 2023?: 5 Wall Street analysts have issued twelve-month price targets for Monopar Therapeutics' stock. Their MNPR share price forecasts range from $2.00 to $24.00. On average, they expect the company's share price to reach $11.33 in the next twelve months. This suggests a possible upside of 1,862.5% from the stock's current price.
View analysts price targets for MNPR or view top-rated stocks among Wall Street analysts.
How have MNPR shares performed in 2023?: Monopar Therapeutics' stock was trading at $2.37 at the beginning of the year. Since then, MNPR shares have decreased by 75.6% and is now trading at $0.5775.
View the best growth stocks for 2023 here.
Are investors shorting Monopar Therapeutics?: Monopar Therapeutics saw a decline in short interest in September. As of September 15th, there was short interest totaling 64,700 shares, a decline of 33.0% from the August 31st total of 96,600 shares. Based on an average daily trading volume, of 250,500 shares, the days-to-cover ratio is currently 0.3 days. Approximately 1.1% of the company's shares are short sold.
View Monopar Therapeutics' Short Interest.
When is Monopar Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our MNPR earnings forecast.
How were Monopar Therapeutics' earnings last quarter?: Monopar Therapeutics Inc. (NASDAQ:MNPR) released its quarterly earnings results on Thursday, August, 10th. The company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.03.

What other stocks do shareholders of Monopar Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Monopar Therapeutics investors own include Entasis Therapeutics (ETTX), Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Akero Therapeutics (AKRO), Chimerix (CMRX), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD) and Aquestive Therapeutics (AQST).
When did Monopar Therapeutics IPO?: (MNPR) raised $9 million in an initial public offering on Thursday, December 19th 2019. The company issued 1,100,000 shares at a price of $8.00 per share. JonesTrading served as the underwriter for the IPO and Arcadia Securities was co-manager.
What is Monopar Therapeutics' stock symbol?: Monopar Therapeutics trades on the NASDAQ under the ticker symbol "MNPR."
How do I buy shares of Monopar Therapeutics?: Shares of MNPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Monopar Therapeutics' stock price today?: One share of MNPR stock can currently be purchased for approximately $0.58.
How much money does Monopar Therapeutics make?: Monopar Therapeutics (NASDAQ:MNPR) has a market capitalization of $8.18 million. The company earns $-10,520,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis.
Does Monopar Therapeutics have any subsidiaries?: The following companies are subsidiares of Monopar Therapeutics: Monopar Therapeutics Pty Ltd, and Monopar Therapeutics SARL.
Read More
How can I contact Monopar Therapeutics?: Monopar Therapeutics' mailing address is 1000 SKOKIE BLVD SUITE 350, WILMETTE IL, 60091. The official website for the company is www.monopartx.com. The company can be reached via phone at 847-388-0349 or via email at info@monopartx.com.

This page (NASDAQ:MNPR) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial